TrialSignal
Clinical trial intelligence report
Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05066165-Jul 28, 2026
NCT ID
NCT05066165
Status
TERMINATED
Phase
Phase 1/2a
Sponsor
Intellia Therapeutics
Executive brief
Investment-Ready Snapshot
Intellia Therapeutics' NTLA-5001 is positioned within the competitive landscape of CAR-T and TCR therapies for Acute Myeloid Leukemia (AML). The termination of this trial indicates a strategic pivot towards an allogeneic version of the therapy, which may enhance scalability and address manufacturing challenges associated with autologous therapies. The AML market is characterized by a growing demand for innovative treatments, particularly in relapsed/refractory cases, suggesting potential for significant market capture if the allogeneic version demonstrates safety and efficacy. Stakeholders should monitor developments closely as the allogeneic approach may offer a competitive edge over existing therapies.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05066165
Indication
Acute Myeloid Leukemia
Modality
gene therapy
Target
WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9
Intervention
Arm 1: NTLA-5001, Arm 2: NTLA-5001
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.